Tenofovir alafenamide fumarate. Issue 1 (7th February 2022)

• Record Type: Journal Article
• Authors: Lee, William A; Cheng, Andrew K
• Is Part Of: Antiviral therapy. Volume 27:Issue 1(2022)
• Publication Date: 2022-02-07
• Subjects: tenofovir -- tenofovir alafenamide fumarate -- HIV -- HBV -- PrEP -- nucleotide -- nucleoside; Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.1177/13596535211067600
• Languages: English
• ISSNs: 1359-6535

Abstract

Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV. Due to its selectivity for these tissues, lower total doses of TAF can be administered relative to tenofovir disoproxil fumarate (TDF) which results in improved bone and renal biomarkers. Tenofovir alafenamide fumarate has become the "backbone" of multiple combination products for the treatment of HIV, combined with emtricitabine for PreP and as a monotherapy for the treatment or HBV.